- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio State University accepted for presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting, marking the trial’s first appearance at a scientific meeting - - Glioblastoma is the most common malignant primary brain tumor in the U.S. - JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alpha T ...